Literature DB >> 17652317

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.

Margaret May1, Jonathan A C Sterne, Martin Shipley, Eric Brunner, Ralph d'Agostino, Peter Whincup, Yoav Ben-Shlomo, Andrew Carr, Bruno Ledergerber, Jens D Lundgren, Andrew N Phillips, Joseph Massaro, Matthias Egger.   

Abstract

BACKGROUND: Many HIV-infected patients on highly active antiretroviral therapy (HAART) experience metabolic complications including dyslipidaemia and insulin resistance, which may increase their coronary heart disease (CHD) risk. We developed a prognostic model for CHD tailored to the changes in risk factors observed in patients starting HAART.
METHODS: Data from five cohort studies (British Regional Heart Study, Caerphilly and Speedwell Studies, Framingham Offspring Study, Whitehall II) on 13,100 men aged 40-70 and 114,443 years of follow up were used. CHD was defined as myocardial infarction or death from CHD. Model fit was assessed using the Akaike Information Criterion; generalizability across cohorts was examined using internal-external cross-validation.
RESULTS: A parametric model based on the Gompertz distribution generalized best. Variables included in the model were systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose, diabetes mellitus, body mass index and smoking status. Compared with patients not on HAART, the estimated CHD hazard ratio (HR) for patients on HAART was 1.46 (95% CI 1.15-1.86) for moderate and 2.48 (95% CI 1.76-3.51) for severe metabolic complications.
CONCLUSIONS: The change in the risk of CHD in HIV-infected men starting HAART can be estimated based on typical changes in risk factors, assuming that HRs estimated using data from non-infected men are applicable to HIV-infected men. Based on this model the risk of CHD is likely to increase, but increases may often be modest, and could be offset by lifestyle changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652317     DOI: 10.1093/ije/dym135

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  8 in total

1.  Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.

Authors:  Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 2.  Noninvasive assessment of HIV-related coronary artery disease.

Authors:  Louis H Miller; John T Coppola
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

3.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

Review 4.  Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population.

Authors:  Ralph B D'Agostino
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

5.  Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.

Authors:  A Antinori; S Rusconi; N Gianotti; T Bini; D Mancusi; R Termini
Journal:  Drug Des Devel Ther       Date:  2019-05-14       Impact factor: 4.162

6.  Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Authors:  Kathy Petoumenos; Signe W Worm; Eric Fontas; Rainer Weber; Stephane De Wit; Mathias Bruyand; Peter Reiss; Wafaa El-Sadr; Antonella D'Arminio Monforte; Nina Friis-Møller; Jens D Lundgren; Matthew G Law
Journal:  J Int AIDS Soc       Date:  2012-10-10       Impact factor: 5.396

7.  Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study.

Authors:  Teri-Louise Davies; Mark Gompels; Sarah Johnston; Begoña Bovill; Margaret T May
Journal:  BMJ Open       Date:  2013-10-25       Impact factor: 2.692

8.  Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons.

Authors:  Max Weyler Nery; Celina Maria Turchi Martelli; Erika Aparecida Silveira; Clarissa Alencar de Sousa; Marianne de Oliveira Falco; Aline de Cássia Oliveira de Castro; Jorge Tannus Esper; Luis Carlos Silva e Souza; Marília Dalva Turchi
Journal:  ScientificWorldJournal       Date:  2013-10-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.